

Special Issue

An Update on Mechanisms and Treatments for Thyroid Cancer in Current Oncology

Message from the Guest Editor

Thyroid cancer (TC) ranked 9th in terms of malignant tumor incidence worldwide in 2020 and 5th among females, thereby establishing itself as a significant threat to population health. The primary approaches for treating TC involve surgery, often supplemented by 131I therapy, radiotherapy, endocrine therapy, and biomarker-targeted therapy. We are pleased to invite you to publish papers spanning basic, translational, and other aspects of thyroid cancer. Original contributions should encompass a broad spectrum of topics within the field, spanning from molecular and cellular biology to immunology, biochemistry, physiology, pathology, and the treatment of both pediatric and adult thyroid cancer. A special emphasis will be placed on thyroid cancer therapy and the molecular mechanisms. This Special Issue aims to original research articles and comprehensive reviews related to thyroid cancer. We look forward to receiving your contributions.

Guest Editor

Dr. Zhilong Ai

Department of Surgery (Thyroid & Breast), Zhongshan Hospital, Fudan University, Shanghai, China

Deadline for manuscript submissions

closed (28 February 2025)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/184401

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).